Geriatric Hip Disorders
Conditions
Interventions
Group R:20 mL of 0.25% ropivacaine
Group RLB:20 mL of 0.25% ropivacaine + 0.5 mg butorphanol
Group RMB:20 mL of 0.25% ropivacaine + 1 mg butorphanol
Group RHB:20 mL of 0.25% ropivacaine + 2 mg butorphanol
Sponsors
Fuzhou Second General Hospital
Eligibility
Sex/Gender
All
Age
65 Years to 85 Years
Inclusion criteria
Inclusion criteria: The enrolled subjects were patients undergoing total hip arthroplasty, aged 65–85 years, with ASA physical status I–III and a body mass index (BMI) of 18.5–30 kg/m².
Exclusion criteria
Exclusion criteria: Exclusion criteria comprised patients with chronic pain, opioid use within 24 hours preoperatively, allergies to ropivacaine or butorphanol, coagulation disorders, infection at the puncture site, severe systemic diseases, or refusal to participate.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The duration of sensory block; | — |
Secondary
| Measure | Time frame |
|---|---|
| Visual Analog Scale for Pain(VAS);Number of presses for patient-controlled intravenous analgesia (PCIA);The first pressing time of patient - controlled intravenous analgesia (PCIA);The first additional administration time of other analgesics;The first time of getting out of bed;Effects on movement, functional recovery, and exercise;Postoperative hospital stay;Active range of motion (AROM) of the hip joint;Quadriceps muscle strength;Hip joint replacement postoperative outcome score (Harris score);Postoperative complications; | — |
Countries
China
Contacts
Public ContactChen Shiwei
Fuzhou Second General Hospital,Fuzhou,China
Outcome results
None listed